Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological Folate Metabolism Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MTHFD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MTHFD2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays and biophysical binding studies. |
View MTHFD2 Products |
| Gene Delivery | MTHFD2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and metabolic tracing. |
View MTHFD2 Products |
| Benchmark Ab | Anti-MTHFD2 Antibody Recombinant positive control for western blot, IHC, and target engagement validation. |
View MTHFD2 Products |
| Validator | MTHFD2 siRNA Set For knockdown verification and target validation in cancer cell lines. |
View MTHFD2 Products |
| Related Target A | MTHFD1 Cytosolic isoform. Essential counter-screening target to ensure drug selectivity and minimize off-target toxicity. |
View MTHFD1 Products |
| Related Target B | SHMT2 Mitochondrial serine hydroxymethyltransferase. Upstream enzyme in the mitochondrial one-carbon pathway, synergistic target for metabolic oncology. |
View SHMT2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against cytosolic MTHFD1 to avoid systemic toxicity | High-purity human MTHFD1 and MTHFD2 recombinant proteins available for comparative SPR/enzymatic assays |
| Assay reproducibility with unstable enzyme preparations | Sequence-verified, highly stable recombinant proteins with theoretical MW verification and endotoxin control |
| Lack of reliable positive control antibodies for intracellular target validation | Recombinant benchmark antibodies sequence-verified for high specificity in Western Blot and IHC applications |
| False positives in cellular phenotypic screens | Sequence-validated siRNA pools included for target-specific knockdown verification |
Live MTHFD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MTHFD2 therapeutics is intensifying, with major players shifting focus from traditional global metabolic inhibitors to highly selective small molecule inhibitors and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific vulnerabilities of mitochondrial one-carbon metabolism in solid tumors and hematological malignancies, while strictly avoiding the systemic toxicity associated with cytosolic folate pathway inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | AstraZeneca, Academic Institutions | Solid Tumors (NSCLC, Breast Cancer), AML | High-throughput enzymatic assays (Need highly stable active MTHFD2 and MTHFD1 for selectivity screening) |
| Targeted Protein Degraders (PROTACs) | Biotech Startups, Academic Labs | Hematological Malignancies, Refractory Cancers | Target engagement and degradation kinetics (Need high-purity recombinant proteins and lentivirus for stable cell line generation) |